Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Galliford Try FY profit, revenue seen ahead of analysts' expectations

(Sharecast News) - Construction group Galliford Try said on Wednesday that full-year profit and revenue were set to be ahead of analysts' expectations. In an update on trading for the year to 30 June, it said the strong performance reported at the half-year results, notably in its water and highways businesses, continued through the second half of the year.

As a result, it now expects full-year revenue and adjusted pre-tax profit "slightly" above the upper end of current analyst forecasts of between £1.86bn and £1.89bn and £40.1m and £41.6m, respectively.

Galliford said the stronger trading is expected to deliver further margin progression towards its 2030 sustainable margin target of 4% and previously-communicated margin target of 3% in 2026.

Chief executive Bill Hocking said: "I am delighted that all our operations continued to perform strongly throughout the second half of the year and we expect to report another year of increased revenue and profit in September.

"Our balance sheet strength and reputation continue to be key to all stakeholders. We welcome the Government's commitment to invest in improving the UK's social and economic infrastructure and affordable housing.

"As a UK only contractor, our confidence in the future is supported by our high-quality order book as well as a long-term pipeline of future opportunities in key sectors as supported by the investment proposals in last month's Spending Review and UK Infrastructure Strategy plans."

At 0900 BST, the shares were up 3.3% at 433.90p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.